ストックスクリーナーアプリを入手
39.77
4.01%
-1.66
前日終値:
$41.43
開ける：
$40.86
24時間の取引高:
436.66K
Relative Volume:
1.09
時価総額：
$1.91B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-5.53%
1か月 パフォーマンス:
+6.71%
6か月 パフォーマンス:
+235.33%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$38.13
$41.83
1週間の範囲:
$38.13
$41.83
52週間の値動き範囲:
$6.71
$43.29
Maze Therapeutics Inc Stock (MAZE) Company Profile
名前
Maze Therapeutics Inc
セクター
電話
(650) 850-5070
住所
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
MAZE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
39.77 | 1.99B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | 開始されました | Wells Fargo | Overweight |
| 2025-11-14 | 開始されました | Raymond James | Outperform |
| 2025-09-02 | 開始されました | BTIG Research | Buy |
| 2025-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-08 | 開始されました | Wedbush | Outperform |
Maze Therapeutics Inc (MAZE) 最新ニュース
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 4.9% – Here’s Why - Defense World
Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9%Here's Why - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Maze Therapeutics SVP, finance sells $606k in shares By Investing.com - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) CMO Sells $1,825,200.00 in Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock - MarketBeat
Maze Therapeutics SVP, finance sells $606k in shares - Investing.com
Maze Therapeutics Insider Sold Shares Worth $1,825,355, According to a Recent SEC Filing - marketscreener.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Growth Recap: Is Maze Therapeutics Inc stock trading at a premium valuationEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
How Maze Therapeutics Inc. stock benefits from tech adoptionMACD Histogram Signals & Free Fast Track Wealth Growth - bollywoodhelpline.com
New way to pay for at‑home AI neurorehab aims to widen access - Stock Titan
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital - MarketBeat
Maze Therapeutics price target raised to $46 from $34 at Guggenheim - MSN
Fundamentals Check: How Maze Therapeutics Inc. stock benefits from tech adoptionWeekly Stock Recap & Expert Approved Trade Ideas - Улправда
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Lifesci Capital - Defense World
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com Canada
What sentiment indicators say about Maze Therapeutics Inc. stockEarnings Risk Summary & Community Shared Stock Ideas - DonanımHaber
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy - MarketBeat
What dividend safety score for Maze Therapeutics Inc. stockWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study - Investing.com Canada
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics - Yahoo Finance
Frazier Life Sciences Management L.P. Buys 438,274 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2%Time to Sell? - MarketBeat
CW Advisors LLC Purchases Shares of 30,235 Maze Therapeutics, Inc. $MAZE - MarketBeat
Investment Report: How Maze Therapeutics Inc stock benefits from tech adoptionJuly 2025 Market Mood & Accurate Buy Signal Alerts - BỘ NỘI VỤ
Maze Therapeutics (MAZE) Price Target Increased by 11.37% to 44.12 - Nasdaq
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wells Fargo Initiates Coverage of Maze Therapeutics (MAZE) with Overweight Recommendation - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week HighTime to Buy? - MarketBeat
Maze Therapeutics stock price target raised to $60 from $50 at H.C. Wainwright - Investing.com Canada
A significant driver of top-line growth: Maze Therapeutics Inc (MAZE) - setenews.com
MAZE Crosses Above Average Analyst Target - Nasdaq
Maze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com Canada
HC Wainwright & Co. Maintains Maze Therapeutics (MAZE) Buy Recommendation - Nasdaq
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026, driving major growth - TradingView
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026 - TradingView
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE - MarketBeat
Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Technical Analysis of Maze Therapeutics, Inc. (NASDAQ:MAZE) - TradingView
Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4%Should You Buy? - MarketBeat
Maze Therapeutics Inc (MAZE) 財務データ
Maze Therapeutics Inc (MAZE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):